Introduction {#s0001}
============

For some years, there has been a great renewal of interest in native vitamin D and its major involvement in osseous and non-osseous effects in the organism, whether in general or specific populations. Native vitamin D insufficiency is strongly present in Chronic Kidney Disease (CKD), widely observed in chronic hemodialysis (CHD), of multifactorial origin, and correlated with high morbidity and mortality \[[@CIT0001]\]. Vitamin D is one of the major biochemical parameters in entity mineral and bone disorders (MBD), a concept developed in 2005 and published in 2009 by Kidney Disease Improving Global Outcomes (KDIGO) to describe all abnormalities of phosphocalcic metabolism observed in patients with CKD \[[@CIT0004]\]. Following a better illustration of the role of vitamin D in CKD-MBD, the use of vitamin D supplementation in patients with CKD over the past two decades has been significantly increased, but there is no consensus for vitamin D, particularly in patients with CHD because of the scarcity of clinical trials conducted on this topic. The aim of this mini-review is to briefly present the physiopathologic elements of native vitamin D, analyze the results of the main published clinical trials, and to discuss the recommendations concerning native vitamin D supplementation in CHD.

Physiopathology of native vitamin D and special features in hemodialysis {#s0002}
========================================================================

Vitamin D~3~ (cholecalciferol) and vitamin D~2~ (ergocalciferol) constitute the two forms at the origin of native vitamin D. More than 90% comes from ultraviolet sun rays of type B (UVB) and less than 10% is of nutritional plant and animal origin. Its half-life is 6 months and it is mainly stored in adipose tissue \[[@CIT0005]\]. As a result, thin persons have a lower storage capacity and may easily become deficient, while obese patients require higher doses of vitamin D to reach their physiologic needs. Vitamin D (D~2~ and D~3~) is transported in the blood and undergoes a first hydroxylation in the liver at the carbon 25 position under the action of D-25 hydroxylase, to produce 25 hydroxyvitamin D (25(OH) D) or calcidiol. Calcidiol undergoes a second hydroxylation in the kidney at the carbon 1 position under the action of D-1,25 hydroxylase to produce 1,25 dihydroxyvitamin D (1,25(OH)~2~D) or calcitriol. There is a pathway of calcitriol inactivation, 24 hydroxylase, the expression of which in the proximal renal tubule is stimulated by Fibroblast Growth Factor 23 (FGF23) and calcitriol. 25(OH)D, precursor of active vitamin D, has a half-life of 15--30 days and is the best marker of the vitamin D status of the organism. Its production is not well-regulated and remains highly dependent on the body\'s production of vitamin D~2~ and D~3~ under the main action of UVB rays. The more vitamin D is synthesized, the more 25(OH)D is produced. It is very important to specify the three groups of forms of vitamin D supplementation usually used to treat bone disorders of CKD. The first group corresponds to native vitamin D: vitamin D~2~ analogs, vitamin D~3~ analogs, and calcifediol (25(OH)D~3~). The second group corresponds to active analog vitamin D, in the form of nonselective vitamin D-receptor activators, such as calcitriol (first generation) and alfacalcidol 1$\alpha$ OHD~3~ (second generation). The third group corresponds to active analog vitamin D, in the form of selective vitamin D-receptor activators, such as paricalcitol 19-nor-1$\alpha~$(third generation) and alfacalcidol 1$\alpha$ OHD~3~ (second generation) 25 hydroxyvitaminD~2~, and doxercalciferol 1$\alpha$ hydroxyvitaminD~2~. The term selective means that the molecule acts mostly on the parathyroid gland, more so than on intestine and bone, resulting in lower serum calcium and phosphorus blood concentrations. In this review, we will use the term native vitamin D to refer to the two vitamin molecules: vitamin D~3~ (Cholecalciferol) and vitamin D~2~ (Ergocalciferol).

Bone and mineral disorders (BMD) comprise one of the earliest, most common, and most serious complications of CKD whose severity increases with the severity of chronic kidney failure. This group of disorders corresponds to a wide spectrum of disturbances affecting three aspects of phosphocalcic metabolism; biological abnormalities of calcium, phosphorus, parathormone, vitamin D, and FGF23; the morpho-histological aspect of bone (bone volume, bone turnover, bone mineralization) and diffuse calcification of soft tissue, blood vessels, and cardiac valves. The main form encountered is secondary hyperparathyroidism, which is biologically characterized by FGF23 elevation, hypocalcemia, and hyperphosphoremia, vitamin D deficiency, and stimulation of parathyroid hormone secretion \[[@CIT0006],[@CIT0007]\]. In this context, the deficit in active vitamin D is largely related to the decrease in the production of 1$\alpha$ hydroxylase, secondary to renal parenchymal fibrosis and the production of FGF23, but also to the decrease in the production of 25(OH)D.

The definition of 25(OH)D status among patients in CHD has not given rise to any recent consensual revision. At this time, we use that developed by the KDIGO 2009 group and in which vitamin D insufficiency is defined by a vitamin D level between 16 and 30 ng/mL and vitamin D deficiency by a level of \<16 ng/mL \[[@CIT0004]\]. A related status of severe deficiency is defined by a vitamin D level of \<5 ng/mL. On the one hand, it is important to point out that these thresholds were validated in the general population among healthy persons, in whom thresholds were set based on studying the concentration level of 25(OH)D, from which the value of plasma parathormone (PTH) may increase. This threshold of 30 ng/mL was used for several studies in which the value of plasma PTH was lowered for plasma values of vitamin D \> 30 ng/mL in a population of osteoporotic patients being treated with bisphosphonates, a medication that lowers the plasma concentration of PTH, and not in patients with CKD \[[@CIT0008]\]. In the latter, variations in vitamin D concentration are closely related to calciotropic and phosphaturic hormones such as PTH and FGF23, calcemia, phosphoremia, medications interfering with phosphocalcic metabolism, as well as to other clinical and biological characteristics of the CHD patient. We use default thresholds for CHD patients close to those retained for the general population without definite scientific proof. On the other hand, the toxicity threshold of vitamin D is also poorly defined in CHD patients. It is very important to specify that resulting complications, especially cardiovascular calcifications, are strongly correlated with high morbi-mortality in CHD. Although the toxicity threshold of vitamin D is 150 ng/mL in the general population, it seems advisable not to exceed the threshold of 80 ng/mL in CHD patients. The rationale is to avoid the appearance not only of complications specific to CKD, such as valvular, cardiac, and vascular calcifications following increased intestinal absorption of phosphorus and calcium, but also other pathologies not specific to CKD, particularly neoplasia \[[@CIT0011],[@CIT0012]\]. These proposed thresholds are not very precise because they are not really established, but are rather 'desirable' or 'recommended' values within acceptable ranges, in view of achieving optimal control of phosphocalcic and osseous metabolism, and of the cardiovascular, immune, and inflammatory systems. Vitamin D insufficiency varies according to numerous parameters, the stage of CKD (greater deficiency in case of ESRD), factors linked to CKD, and other factors independent of CKD. Factors nonspecific to CKD and the most frequently found, comprise dietary restrictions with interdiction of numerous vitamin D-enriched products, lack of appetite, insufficient sun exposure, diminution of cutaneous synthesis, the season of the blood sample, advanced age, female gender, ethnicity, obesity, diabetes, pigmented skins, and socio-cultural habits \[[@CIT0013]\].

Other specific and molecular factors are also involved in vitamin D deficiency in CHD, such as resistance and/or decreased sensitivity of the tissue receptors of vitamin D, decreased hepatic synthesis of CYP24A1, decreased tubular absorption of 25(OH)D due to the decrease of megaline, decreased activity of 1$\alpha$ hydroxylase secondary to uremia and acidosis, and increased activity of 24--25(OH)~2~D \[[@CIT0016]\]. Secondary hyperparathyroidism, decrease of bone mineral density, muscular weakness, falls and fractures, metabolic syndrome and obesity, insulin resistance, left ventricular hypertrophy, atherosclerosis, vascular and valvular calcifications, alteration of mental faculties, and progression of kidney disease from the pre-dialysis stage to the dialysis stage, are the main consequences of vitamin D deficiency in CHD patients \[[@CIT0020]\]. The association of mortality and vitamin D has been the subject of many studies which converge on a strong association between mortality and vitamin D deficiency in CKD, including in the early stages \[[@CIT0025],[@CIT0026]\]. Pilz et al. noted in their meta-analysis that the decrease in vitamin D plasma concentration of 10 ng/mL was associated with a 14% increase of mortality risk and the decrease of 25(OH)D and of 1.25(OH)~2~D was associated with mortality among patients on hemodialysis. In the French cohort of Jean et al., the risk of mortality increased up to 30% when vitamin D plasma concentrations were less than 18 ng/mL \[[@CIT0027]\].

Randomized clinical trials {#s0003}
==========================

Is substitution for vitamin D deficiency required in CHD patients? The answer is increasingly obvious in view of the central role of vitamin D in MBDs, the prevention of fractures and the optimization of extra-osseous effects of vitamin D, especially cardiovascular. While substitution in vitamin D deficiency is no longer a matter of debate, doses, methods of administration, and threshold definitions are still far from being well-established.

Seven double-blind randomized clinical trials have evaluated native vitamin D supplementation in adult CHD patients. These clinical trials began between 2007 and 2012 and studied relatively small numbers of patients with an average of 50 patients for the two groups (vitamin D versus placebo). The results of the main double-blind clinical trials over the last decade are reported in [Table 1](#t0001){ref-type="table"}. The choice of clinical trials mentioned in [Table 1](#t0001){ref-type="table"} is based on the fact that these are the only randomized controlled double-blind (placebo versus native vitamin D) trials published in the literature during the last two decades concerning native vitamin D supplementation in the CHD patient.

###### 

Results of the main randomized controlled trial Double-Blind (RCT- DB) published in the last decade in adult chronic hemodialysis patients (\>18 years).

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Randomized Trial                                                     Bhan et al. \[[@CIT0028]\]           Armas et al. \[[@CIT0029]\]                         Delanaye et al. \[[@CIT0030]\]                  Marckmann et al. \[[@CIT0031]\]                                                 Wasse et al. \[[@CIT0032]\]                                           Hewitt et al. \[[@CIT0033]\]                                  Massart et al. \[[@CIT0034]\]
  -------------------------------------------------------------------- ------------------------------------ --------------------------------------------------- ----------------------------------------------- ------------------------------------------------------------------------------- --------------------------------------------------------------------- ------------------------------------------------------------- ---------------------------------------
  Study period                                                         2009--2013                           2007--2010                                          2009--2010                                      2009--2009                                                                      2009--2010                                                            2011--2011                                                    2008--2009

  RCT-double blind                                                     Placebo versus vitD                  Placebo versus vitD                                 Placebo versus vitD                             Placebo versus vitD                                                             Placebo versus vitD                                                   Placebo versus vitD                                           Placebo versus vitD

  Mono or multicenter                                                  Multicenter                          Multicenter                                         Multicenter                                     Monocenter                                                                      Monocenter                                                            Monocenter                                                    Multicenter

  Number of patients                                                                                                                                                                                            All patients *N* = 52                                                                                                                                                                                                

  Total                                                                *N* = 105                            *N* = 42                                            *N* = 30                                        Hemodialysis group *N* = 27                                                     *N* = 52                                                              *N* = 60                                                      *N* = 55

  VitD group                                                           Weekly arm vitD = 36                 VitD = 20                                           VitD = 16                                       VitD G = 13                                                                     VitD = 25                                                             VitD= 30                                                      VitD G = 26

  Placebo group                                                        Monthly arm vitD = 33\               Placebo = 22                                        Placebo = 14                                    Placebo G =14                                                                   Placebo = 27                                                          Placebo = 30                                                  Placebo G = 29
                                                                       Placebo arm = 36                                                                                                                                                                                                                                                                                                                                             

  Mean age, years\                                                     Weekly vitD: 53 $\pm$17\             VitD: 57.6\                                         VitD: 75 $\pm$ 9\                               For all patients\                                                               VitD: 49 $\pm$ 13\                                                    VitD: 60\                                                     VitD: 62 $\pm$ 12\
  VitD group\                                                          Monthly vitD:58 $\pm$16\             Placebo: 54.3                                       Placebo: 73 $\pm ~$12                           VitD: 71\                                                                       Placebo: 52 $\pm ~$14                                                 Placebo: 67                                                   Placebo: 66 $\pm$12
  Placebo group                                                        Placebo: 59 $\pm$17                                                                                                                      Placebo: 68                                                                                                                                                                                                         

  Sex, Male, %                                                         Weekly vitD: 69.4\                   VitD: 70\                                           VitD: 75\                                       For all patients\                                                               VitD: 60\                                                             VitD: 53\                                                     VitD: 69\
                                                                       Monthly vitD: 84.9\                  Placebo: 72                                         Placebo: 64                                     VitD: 73\                                                                       Placebo: 63                                                           Placebo: 43                                                   Placebo: 55
                                                                       Placebo: 80.6                                                                                                                            Placebo: 76                                                                                                                                                                                                         

  Ethnicity\                                                           Weekly: 63.6 versus 36.1\            VitD: 50 versus 50\                                 All patients were Caucasian                     Not mentioned                                                                   VitD: 4 versus 96\                                                    VitD: 50 versus 50\                                           VitD: 97 versus 3\
  White versus Black, %                                                Monthly: 63.6 versus 27.3\           Placebo: 68 versus 27                                                                                                                                                               Placebo:19 versus 81                                                  Placebo: 36.7 versus 63.3                                     Placebo: 92 versus 8
                                                                       Placebo: 61.1 versus 25                                                                                                                                                                                                                                                                                                                                      

  Mean of Body mass index kg/m^2^                                      Weekly: 30.5 $\pm ~$9.8\             VitD: 26.7\                                         No mentioned                                    VitD: 25.9\                                                                     VitD: 30.1 $\pm ~$8.4\                                                VitD: 26.6 $\pm ~$6.4\                                        VitD: 26.7 $\pm ~$7.3\
                                                                       Monthly: 32.0 $\pm ~$9.5\            Placebo: 26.4                                                                                       Placebo: 24.6                                                                   Placebo: 27.6 $\pm ~$7.7                                              Placebo: 31.3 $\pm ~$9.5                                      Placebo: 26.8 $\pm ~$5.9
                                                                       Placebo: 30.1 $\pm ~$6.5                                                                                                                                                                                                                                                                                                                                     

  Duration of the study                                                16 weeks                             15 weeks                                            12 months                                       8 weeks                                                                         6 weeks                                                               06 months                                                     39 weeks

  Baseline serum vitD in vitD group ng/mL                              22                                   13                                                  12                                              8.5                                                                             14                                                                    17                                                            17

  Administered dose of vitD                                            Weekly: 50 000 IU/week\              10 000 IU / week/15 weeks                           25 000 IU each 2 weeks for 12 months per os     40 000 IU/ week/8 weeks                                                         200 000 IU/ week/ 3 weeks                                             50 000 IU/ week/8weeks\                                       25 000 IU/ week/ 13 weeks\
                                                                       /4 weeks\                                                                                                                                                                                                                                                                                      then 50.000 IU/ Month/4 months                                Then with dose adjustment
                                                                       Monthly: 50.000 IU/ month/3 months                                                                                                                                                                                                                                                                                                                           

  Cumulative dose of vitD                                              Weekly :200 000 IU\                  150 000 IU                                          600 000 IU                                      320 000 IU                                                                      600 000 IU                                                            600 000 IU                                                    325 000 IU
                                                                       Monthly :150 000 IU                                                                                                                                                                                                                                                                                                                                          

  Type of administered vitD                                            Ergocalciferol                       Cholecalciferol                                     Cholecalciferol                                 Cholecalciferol                                                                 Cholecalciferol                                                       Cholecalciferol                                               Cholecalciferol

  Mean of serum vitD After supplementation\                            Weekly vitD: 48\                     23.6\                                               33\                                             46\                                                                             52.4 $\pm ~$18\                                                       39 $\pm ~$10\                                                 35.2 $\pm ~$12\
  in vitD group ng/mL                                                  Monthly vitD: 36\                    (*p* \< 0.001)                                      (*p* \< 0.001)                                  (*p* \< 0.001)                                                                  (*p* \< 0.001)                                                        (*p* = 0.04)                                                  (*p* \< 0.001)
                                                                       (*p* \< 0.001)                                                                                                                                                                                                                                                                                                                                               

  Delta drop in serum vitD                                             27 ng/mL                             10 ng/mL                                            11 ng/mL                                        51 ng/mL                                                                        38 ng/mL                                                              18 ng/mL                                                      18 ng/mL

  Percentage of patients who achieve 25 OHD\> 30 ng/mL in vitD group   At the 12th week:\                   Not mentioned                                       At the 12th month : 71%                         At the 8th week : 100%                                                          At the 6th week : 90%                                                 Not mentioned                                                 At the 13th week : 70%
                                                                       Weekly arm: 91%\                                                                                                                                                                                                                                                                                                                                             
                                                                       Monthly arm: 65%                                                                                                                                                                                                                                                                                                                                             

  Effect on serum calcium                                              No difference                        No difference                                       No difference                                   No difference                                                                   No difference                                                         No difference                                                 No difference

  Effect on serum phosphorus                                           No difference                        No difference                                       No difference                                   No difference                                                                   No difference                                                         Has decreased                                                 No difference

  Effect on serum PTH                                                  No difference                        No difference                                       Has decreased                                   No difference                                                                   No difference                                                         No difference                                                 No difference

  Progression of vascular calcification                                Not studied                          Not studied                                         Increased calcification scores in both groups   Not studied                                                                     Not studied                                                           Not studied                                                   No difference

  Value of serum 1.25 OH~2~D                                           No difference                        Has increased                                       Not studied                                     No difference                                                                   Has increased                                                         Has increased                                                 Has increased

  Other effects observed in vitD group                                 No effect on :\                      No difference according to diabetes and ethnicity   Not studied                                     No effect on muscle function or biomarkers related to cardiovascular diseases   No difference in albumin, hemoglobin and lipidbiological biomarkers   No effect on test of functional capacity or muscle strength   No effect on bone turnover parameters
                                                                       FGF-23\                                                                                                                                                                                                                                                                                                                                                      
                                                                       Hospitalization\                                                                                                                                                                                                                                                                                                                                             
                                                                       1-year mortality\                                                                                                                                                                                                                                                                                                                                            
                                                                       Blood pressure                                                                                                                                                                                                                                                                                                                                               

  Adverse effect in vitD group                                         Similar between the three groups     Not mentioned                                       No hypercalcemic episodes                       Three hypercalcemic episodes                                                    Not mentioned                                                         No difference in falls and fractures                          One hypercalcemic episode

  Drugs taken\                                                         Calcitriol                           Calcitriol                                          Phosphate binders                               Calcitriol,\                                                                    Calcitriol                                                            Calcitriol,\                                                  Calcitriol, cinacalcet
  Calcitriol,\                                                                                                                                                                                                  Cinacalcet, phosphate binders                                                                                                                         calcium                                                       
  Cinacalcet, Calcium                                                                                                                                                                                                                                                                                                                                                                                                               
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The cumulative doses administered throughout the duration of the study show great variation, from 150 000 to 600 000 IU, as do the modes of administration.

In the prospective study of Zitt et al., native vitamin D substitution adapted to the body weight of patients on CHD and peritoneal dialysis did not show significant difference concerning the increase in calcemia and phosphoremia between the start of the study and the end of 26 weeks of treatment, but the decrease in the value of serum PTH was significant \[[@CIT0035]\]. It should be noted that in this study, certain patients were already receiving calcitriol and cinacalcet, which may largely explain the PTH decrease, even though the two groups were initially similar. In a small clinical trial conducted by Mieczkowski et al. in Poland, the nine patients included in the native vitamin D arm (versus a control group) received low doses, 72 000 IU in 12 months, and the difference between the two groups after a year of treatment was significant concerning levels of 25(OH)D and 1.25(OH)~2~D, without significant impact on calcemia, phosphoremia, or PTH \[[@CIT0036]\]. The main limitations of this study are the small sample and lack of a placebo group.

Bhan et al. conducted one of the largest clinical trials, with 105 patients in three groups (placebo versus vitamin D weekly and vitamin D monthly). It did not show statistically significant differences concerning calcemia, phosphoremia, or PTH, with equal incidence of secondary effects between the three groups \[[@CIT0028]\]. However, the weak results of this trial may be largely explained by the low doses of vitamin D administered over short periods (150 000--200 000 IU in 1--3 months).

Armas et al. conducted the first controlled randomized double-blind trial in 2007 with relatively lower vitamin D doses, i.e(0).150 000 IU for 15 weeks, and noted no significant difference between the two groups concerning serum calcium, phosphorus or PTH, even though the 1.25(OH)~2~D increased in the treated group \[[@CIT0029]\]. In 2009, Delanaye et al. conducted a controlled randomized double-blind trial with high vitamin D doses of 600 000 IU, but administered for 12 months, and noted no significant difference concerning serum calcium and phosphorus \[[@CIT0030]\]. In this trial, the authors found that the delta PTH level significantly decreased in the treated group, but all patients received calcitriol, calcium, and phosphate binders, and the level of 1.25(OH)~2~D was not studied. The availability of 1.25 (OH)~2~D in CHD patients is important because availability in physiologic quantity allows optimization of osseous and extra-osseous effects of vitamin D. Its production in this context remains dependent on extrarenal, or intracellular, production that is itself dependent on intracellular availability of an adequate quantity of 25(OH)D. Only sufficient native vitamin D supplementation allows sufficient production of calcitriol.

Marckman et al., Wass et al., Hewitte et al., and Massard et al. \[[@CIT0031]\] noted in their respective clinical trials that vitamin D supplementation was accompanied by a significant increase in calcitriol.

The vitamin D target achieved in the majority of these clinical trials was greater than 30 ng/mL and did not exceed 60 ng/mL, reflecting the safety of both low and relatively high doses of vitamin D over short periods of time or long periods. Admittedly, these clinical trials have not shown any major side effects of vitamin D supplementation, particularly increases in calcium and blood phosphorus, which demonstrates the safe use of native vitamin D in CHD. Thus, the benefit of supplementation appears to be greater than the risk of non-supplementation.

All of these trials are important, but do not provide sufficient and accurate scientific evidence concerning the advantages, consequences and secondary effects of native vitamin D supplementation in CHD. The authors themselves recognize their limitations and recommend larger studies including larger numbers of patients with more rigorous inclusion criteria and standardization of protocols for vitamin D administration (ergocalciferol versus cholecalciferol, doses, duration, season of the study, etc.). It is only the native vitamin D fraction combining D~2~ and D~3~ that is usually measured in clinical trials. An unavoidable question concerns the involvement of each form in phosphocalcic metabolism and the extra-osseous effects on patients in CHD. Only Bhan et al. \[[@CIT0028]\], in their 2009 clinical trial measured native vitamin D as well as its two fractions D~2~ and D~3~ at the start of the study, but end of study values were not reported in the results.

International recommendations {#s0004}
=============================

In light of the results of these clinical trials, what are the recommendations of the main learned societies of nephrology for CHD patients? [Table 2](#t0002){ref-type="table"} summarizes the main recommendations for native vitamin D supplementation in CHD patients according to the several international societies of nephrology. In 2003, Kidney Disease Outcomes Quality Initiative (KDOQI) recommended a correction of vitamin D to reach a threshold of 30 ng/mL without specifying the stage of CKD \[[@CIT0037]\]. In 2017, KDIGO recommended a correction of vitamin D deficiency and insufficiency for CKD from stages 3a--5 dialysis without specifying the target threshold \[[@CIT0038]\]. In 2003, KDOQI had recommended, but only for CKD stages 3 and 4, a measurement of vitamin D (evidence\*) and ergocalciferol (D~2~) supplementation if the 25(OH)D value was \<30 ng/mL (opinion\*). The recommended dose was 50 000 IU per week or month for 6 months depending on the severity of the deficiency. In these 2003 recommendations, the dialyzed patient in stage 5D was not mentioned and the authors questioned the pertinence of supplementing with vitamin D, given the low renal production of 1.25(OH)~2~D. However, recent discoveries in fundamental and clinical research have shown the persistence of weak renal production and the presence of quite high extrarenal production of 1.25(OH)~2~D, which points anew to the importance of vitamin D supplementation in CHD patients \[[@CIT0039]\].

###### 

The main recommendations concerning native vitamin D supplementation in adults chronic hemodialysis patients.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Guidelines                                                                             Recommendations for chronic hemodialysis patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Thresholds   Dose   Duration   Molecule
  -------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------ ------ ---------- ----------
  The KDIGO 2009 (Kidney Disease Improving Global Outcomes) \[[@CIT0004]\]               In patients with CKD stages 3--5 D, we suggest that 25(OH)D (calcidiol) might be measured, and repeated testing determined by baseline values and therapeutic interventions (2 C). We suggest that vitamin D deficiency and insufficiency be corrected using treatment strategies recommended for the general population (2 C)                                                                                                                                                                                                                                                                      None         None   None       None

  The KDOQI 2003 (Kidney Disease Outcomes Quality Initiative) \[[@CIT0037]\]             No recommendation about native vitamin D for dialysis patients. In patients with GFR\< 20 mL/min/1.73 m^2^ and those requiring dialysis, there is no evidence that modest supplementation with ergocalciferol to raise serum 25(OH)D levels to 30--60 pg/mL will increase the plasma levels of 1,25 (OH)~2~D or lower the elevated serum levels of intact PTH                                                                                                                                                                                                                                       None         None   None       None

  KDIGO 2017 \[[@CIT0038]\]                                                              The same recommendation as KDIGO 2009. In patients with CKD G3a--G5D, we suggest that 25(OH)D levels might be measured, and repeated testing determined by baseline values and therapeutic interventions (2 C). We suggest that vitamin D deficiency and insufficiency be corrected using treatment strategies recommended for the general population (2 C)                                                                                                                                                                                                                                         None         None   None       None

  The KDOQI 2010 Commentary on KDIGO 2009 \[[@CIT0040]\]                                 Needs to individualize the decision for whether, when, and how often to measure vitamin D and below what threshold and to what target range to treat. A reasonable approach is to periodically measure 25(OH) D in patients with CKD and initiate treatment if the level is low                                                                                                                                                                                                                                                                                                                     None         None   None       None

  The CSN 2010\                                                                          Until the clinical benefit of correcting nutritional vitamin D 'insufficiency' has been established within the dialysis population or for patients with stages 4 and 5 CKD, it would seem premature to suggest screening with vitamin D assays                                                                                                                                                                                                                                                                                                                                                      None         None   None       None
  Commentary on KDIGO 2009\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  (Canadian Society of Nephrology) \[[@CIT0041]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  The CARI 2006 (Caring for Australasians with Renal Impairment) \[[@CIT0042]\]          No recommendations about native vitamin D for dialysis patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     None         None   None       None

  KWG 2015 (Korean working Group) \[[@CIT0043]\]                                         None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                None         None   None       None

  JSDT 2013 (The Japanese Society for Dialysis Therapy) \[[@CIT0044]\]                   None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                None         None   None       None

  The ERBP 2010 Commentary on KDIGO 2009 (European Renal Best Practice) \[[@CIT0045]\]   None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                None         None   None       None

  UKAR 2011 (United Kingdom Report Annual final version 2015) \[[@CIT0046]\]             Although the benefits are unconfirmed, a reasonable case exists for the measurement of vitamin D in CKD. A pragmatic approach is to measure 25(OH)D at baseline in CKD stage 3 b and above, with a view to correction of insufficiency or deficiency (\>75 nmol/L = repletion, 37.5--75 nmol/L = insufficiency, \<37.5 nmol/L = deficiency). Vitamin D levels need to be interpreted in the context of the patient\'s overall clinical condition, other biochemical abnormalities, and the preexisting therapy. Repeat testing will be determined by baseline value and therapeutic interventions   None         None   None       None
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In 2009, KDIGO suggested, with a lower level of proof, measuring 25(OH)D serum concentration in CKD patients in stages 3, 4, 5, and 5 dialyzed (2 C), and treating as for the general population, but favoring this time form D~3~ of vitamin D and not the D~2~ form as in 2003 (2 C) \[[@CIT0004]\]. The lack of clear recommendations by KDOQI 2003 and KDIGO 2009 explains the enthusiasm and interest brought by certain authors to carrying out clinical trials, mentioned in [Table 1](#t0001){ref-type="table"}, and which tried to provide clear answers, but without strong scientific proof. In addition, none of the American, Canadian, Australian, Asian, European, and English recommendations have specified the targets, doses, duration or the molecule of vitamin D supplementation in the patient on CHD \[[@CIT0040]\]. The European recommendations of 2010 European Renal Best practice (REBP) opted for native vitamin D 12.5 ng/mL as the treatment threshold instead of the threshold of 30 ng/mL, due to the absence of a clear benefit from supplementation beyond 12.5 ng/mL \[[@CIT0045]\]. KDOQI 2003 had recommended the oral use of ergocalciferol (and not cholecalciferol) at relatively high doses of 600 000 IU in 6 months, while ERBP 2010 preferred cholecalciferol without mention of modes of administration. KDIGO 2009 gave no specifications concerning either the molecule or the doses and recommended the same treatment strategy as for the general population.

It is currently well-established that in using spaced doses of vitamin D in the general population, vitamin D~3~ is superior to vitamin D~2~. The half-life of 25(OH)D~3~ is longer than that of 25(OH)D~2~ making it possible to achieve a satisfactory vitamin status for a long time \[[@CIT0047]\]. In 2017, the long awaited KDIGO recommendations were published and despite the results of clinical trials conducted between 2007 and 2013, the recommendations on vitamin D supplementation in CHD were very imprecise and sparse, limited to suggesting correction of any state of insufficiency or deficiency in patients presenting CKD of stage 3A to stage 5D (2C). In this recommendation, CHD patients are considered as patients in CKD stage 3A without taking into account either the special characteristics of CHD patients, or the marked prevalence of vitamin D insufficiency in CHD, or the strong correlation with morbi-mortality in CHD, or the probably greater need for supplementation in order to reduce the harmful consequences of vitamin D insufficiency on phosphocalcic metabolism, the cardiovascular system, immunity and numerous other systems, and functions.

Conclusion {#s0005}
==========

Many questions remain unanswered for CHD patients, who are at high cardiovascular risk with high morbi-mortality: the precise role of each fraction of vitamin D, ergocalciferol versus cholecalciferol; the isolated impact of each fraction of vitamin D on different functions; the optimal target thresholds and the toxicity threshold of native vitamin D; the dose to be administered and treatment duration. Would it not also be more pertinent to supplement in relation to the weight and lean body mass of the patient rather than with standard doses? Only clinical trials that are larger, more rigorous, and more precise with the fewest possible interferences can provide clear answers and guide working groups to more appropriate recommendations that are better adapted to patients in CHD.
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